Moore Capital Management’s Starling Oncology STLN Stock Holding History

Moore Capital Management’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-250,000	Closed	-$2.48M	–	861
2021 Q3	$2.48M	Hold	250,000	–	–	0.04%	399
2021 Q2	$2.48M	Hold	250,000	–	–	0.04%	417
2021 Q1	$2.49M	Hold	250,000	–	–	0.03%	406
2020 Q4	$2.7M	Hold	250,000	–	–	0.03%	319
2020 Q3	$2.59M	Hold	250,000	–	–	0.05%	244
2020 Q2	$2.54M	Buy	+250,000	New	+$2.49M	0.07%	182

Other funds holding STLN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

PGM

Parian Global Management Pound Ridge, New York $30.8M AUM 51.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return

AGM

Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return

SCM

Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Moore Capital Management's STLN Position: Q4 2021 in Review

Moore Capital Management sold out of Starling Oncology (STLN) in Q4 2021, closing a stake of 250,000 shares — an estimated $2.48M sold.

Moore Capital Management first reported a position in STLN in Q2 2020 and held it in 6 quarters. The position peaked at $2.7M in Q4 2020. 21 funds tracked by Wall St. Rank hold STLN as of Q4 2021.

Moore Capital Management reported no remaining Starling Oncology position as of Q4 2021 after selling out during the quarter.
Moore Capital Management sold 250,000 Starling Oncology shares in Q4 2021, an estimated $2.48M.
Moore Capital Management first reported a position in Starling Oncology in Q2 2020 and held it in 6 quarters.
Moore Capital Management's Starling Oncology position peaked at $2.7M in Q4 2020.
21 funds tracked by Wall St. Rank held Starling Oncology as of Q4 2021.

Based on Moore Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.